Member login

Forgot Password?

By using the members area you have already agreed to share your personal information with the BBA so that you can access the members materials. We will store your details only as long as you are a member. Your personal information will not be shared any affiliated companies or third parties. For more information about our Privacy Policy, click here.

Return to login
Better access. Better health
Read our guide to Generic and biosimilars medicines market and pricing
Better access to high quality biological medicines
The British Biosimilars Association (BBA) is the expert sector group of the British Generic Manufacturers Association (BGMA) exclusively focused on biosimilars

The British Biosimilars Association (BBA) is the expert sector group of the British Generic Manufacturers Association (BGMA) exclusively focused on biosimilars.

The members of the BBA ensure access to high quality, safe and effective biosimilar medicines for UK patients. As industry experts, we partner with patients’ representatives, healthcare professionals, regulators and payers to increase understanding and to drive a sustainable environment for the development, production and continuing optimised use of biosimilar medicines across the UK.

For more information about Biosimilars, please take a look at NHS England’s ‘What is a Biosimilar’ document.

Twitter

03.12.2018
Reaction to the proposed changes to the statutory scheme to control the costs of branded health service medicines consultation response from Warwick Smith, Director General @Britishgenerics @BritBiosimilars https://t.co/q286lvxtAg
26.11.2018
RT @NHSEngland: The #NHS is set to save a record £300 million after negotiating deals with five manufacturers on low cost versions of the health service's most costly drug, Simon Stevens announced today. https://t.co/EWwkpB8v9
26.11.2018
RT @NHSEngland: The #NHS is set to save a record £300 million after negotiating deals with five manufacturers on low cost versions of the health service's most costly drug, Simon Stevens announced today. https://t.co/EWwkpAQTL
18.10.2018
RT @MauraOMalley2: Often described as the world's most expensive drug #Humira has come off European patent to much fanfare from @BritBiosimilars; the biosimilar Adalimumab, the costliest drug to the NHS in the UK, "gives a further massive opportunity to treat more patients for less money"